Littérature scientifique sur le sujet « CDK17 »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « CDK17 ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "CDK17"
Liu, Mingfa, Zhennan Xu, Zepeng Du, Bingli Wu, Tao Jin, Ke Xu, Liyan Xu, Enmin Li et Haixiong Xu. « The Identification of Key Genes and Pathways in Glioma by Bioinformatics Analysis ». Journal of Immunology Research 2017 (2017) : 1–9. http://dx.doi.org/10.1155/2017/1278081.
Texte intégralLiang, Kaiwei, Xin Gao, Joshua M. Gilmore, Laurence Florens, Michael P. Washburn, Edwin Smith et Ali Shilatifard. « Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing ». Molecular and Cellular Biology 35, no 6 (5 janvier 2015) : 928–38. http://dx.doi.org/10.1128/mcb.01426-14.
Texte intégralLier, S., I. Rein, S. Lund, A. Lång, E. Lång, N. Meyer, A. Dutta et al. « P10.12.A CDK12/CDK13 inhibition disrupts a transcriptional program critical for glioblastoma survival ». Neuro-Oncology 24, Supplement_2 (1 septembre 2022) : ii51. http://dx.doi.org/10.1093/neuonc/noac174.177.
Texte intégralKohoutek, Jiri, et Dalibor Blazek. « Cyclin K goes with Cdk12 and Cdk13 ». Cell Division 7, no 1 (2012) : 12. http://dx.doi.org/10.1186/1747-1028-7-12.
Texte intégralFan, Zheng, Jennifer R. Devlin, Simon J. Hogg, Maria A. Doyle, Paul F. Harrison, Izabela Todorovski, Leonie A. Cluse et al. « CDK13 cooperates with CDK12 to control global RNA polymerase II processivity ». Science Advances 6, no 18 (29 avril 2020) : eaaz5041. http://dx.doi.org/10.1126/sciadv.aaz5041.
Texte intégralShah, Muzna, Muhammad Fazal Hussain Qureshi, Danish Mohammad, Mahira Lakhani, Tabinda Urooj et Shamim Mushtaq. « CDKs family -a glimpse into the past and present : from cell cycle control to current biological functions ». Asian Pacific Journal of Cancer Biology 5, no 1 (25 février 2020) : 1–9. http://dx.doi.org/10.31557/apjcb.2020.5.1.1-9.
Texte intégralZhang, Bo, Xuelin Zhong, Moira Sauane, Yihong Zhao et Zhi-Liang Zheng. « Modulation of the Pol II CTD Phosphorylation Code by Rac1 and Cdc42 Small GTPases in Cultured Human Cancer Cells and Its Implication for Developing a Synthetic-Lethal Cancer Therapy ». Cells 9, no 3 (4 mars 2020) : 621. http://dx.doi.org/10.3390/cells9030621.
Texte intégralGuiro, Joana, Mathias Fagbemi, Michael Tellier, Justyna Zaborowska, Stephanie Barker, Marjorie Fournier et Shona Murphy. « CAPTURE of the Human U2 snRNA Genes Expands the Repertoire of Associated Factors ». Biomolecules 12, no 5 (14 mai 2022) : 704. http://dx.doi.org/10.3390/biom12050704.
Texte intégralQuereda, Victor, Simon Bayle, Francesca Vena, Sylvia M. Frydman, Andrii Monastyrskyi, William R. Roush et Derek R. Duckett. « Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer ». Cancer Cell 36, no 5 (novembre 2019) : 545–58. http://dx.doi.org/10.1016/j.ccell.2019.09.004.
Texte intégralZhang, Tinghu, Nicholas Kwiatkowski, Calla M. Olson, Sarah E. Dixon-Clarke, Brian J. Abraham, Ann K. Greifenberg, Scott B. Ficarro et al. « Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors ». Nature Chemical Biology 12, no 10 (29 août 2016) : 876–84. http://dx.doi.org/10.1038/nchembio.2166.
Texte intégralThèses sur le sujet "CDK17"
Dust, Sofia [Verfasser]. « Biochemical characterization, regulation, and inhibition of human transcription kinases CDK12 and CDK13 and human cell cycle-related kinase CDK14 / Sofia Dust ». Bonn : Universitäts- und Landesbibliothek Bonn, 2019. http://d-nb.info/1223538028/34.
Texte intégralLianga, Noel. « Cdk1 Regulates Anaphase Onset ». Thesis, Université d'Ottawa / University of Ottawa, 2014. http://hdl.handle.net/10393/31860.
Texte intégralChun, Stella Soyoung. « Identification and validation of CDK13 interacting proteins ». Thesis, University of British Columbia, 2012. http://hdl.handle.net/2429/43130.
Texte intégralMoreira, Juliana. « Expressão e purificação da quinase dependente de ciclina 13 humana em sistema bacteriano ». Universidade de São Paulo, 2014. http://www.teses.usp.br/teses/disponiveis/75/75133/tde-28082014-135313/.
Texte intégralThe cyclin-dependent kinases are proteins that can be classified by their function in the cell cycle or transcriptional control. They are activated in particular steps of the cell cycle depending on their phosphorylation degree, cyclin binding and inhibitory proteins. They act phosphorylating other proteins involved in the cell cycle and transcriptional control, influencing in their activities, ensuring that each step of the cell cycle occur in an ordered sequence. The CDK13 is one of the cyclin-dependent kinases family member, it can bind to L or K cyclins, regulates the alternative splicing and interact with HIV Tat protein, acting as a possible restriction factor, its overexpression decreases the production of some viral proteins, and suppresses the virus production. The DNA corresponding to CDK13 is replicated in cancer cells, mainly of hepatic and colon rectal types; therefore it is a target for inhibitors for cancer therapy. In order to contribute for the studies of this protein, the goal of the project is to express it using methods of recombinant DNA technology. The DNA sequence corresponding to CDK13 was amplified by polymerase chain reaction, after its purification, it was inserted to pCR-Blunt vector and cloned into E. coli DH5α competent cells. However, the DNA wasn\'t released by the BamHI and NdeI restriction enzymes. The Rosetta(DE3) cells transformed with a synthetic plasmid pET28a::CDK13 and grown in auto-induction media expressed the CDK13. After cell lysis and purification by Ni2+ affinity colum, the protein was identified by Western Blot. However, the Rosetta(DE3) cells transformed with the modified synthetic plasmid (that comprehends the DNA region which expresses the binding pocket region) induced in LB media, expressed the CDK13. Yet, it wasn\'t possible to purify the protein in the Ni2+ affinity column.
Krämer, Thomas. « Gastrointestinale Stromatumoren (GIST) : CD117-Expression und klinischer Verlauf / ». Würzburg, 2007. http://opac.nebis.ch/cgi-bin/showAbstract.pl?sys=000253020.
Texte intégralDixon-Clarke, Sarah. « Structure and inhibition of novel cyclin-dependent kinases ». Thesis, University of Oxford, 2015. https://ora.ox.ac.uk/objects/uuid:3c6955c9-469a-4f4b-9577-309ccb57b742.
Texte intégralBondke, Alexander. « Design and synthesis of selective CDK7 inhibitors ». Thesis, Imperial College London, 2014. http://hdl.handle.net/10044/1/43965.
Texte intégralKamkar, Fatemeh. « Pftaire1 (Cyclin Dependent Kinase14) : Role and Function in Axonal Outgrowth During the development of the CNS ». Thesis, Université d'Ottawa / University of Ottawa, 2015. http://hdl.handle.net/10393/32860.
Texte intégralDubbury, Sara Jane. « Cdk12 regulates DNA repair Genes by suppressing intronic polyadenylation ». Thesis, Massachusetts Institute of Technology, 2018. http://hdl.handle.net/1721.1/115596.
Texte intégralThis electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.
Cataloged from student-submitted PDF version of thesis. Vita.
Includes bibliographical references.
During transcription, cyclin-dependent kinases (CDKs) dynamically phosphorylate the C-terminal domain (CTD) of RNA Polymerase II (RNAPII) to recruit factors that coordinate transcription and mRNA biogenesis. Cdk12 phosphorylates Serine 2 (Ser2) of the RNAPII CTD, a modification associated with the regulation of transcription elongation, splicing, and cleavage/polyadenylation. Unlike other transcriptional CDKs that regulate most expressed genes, Cdk12 depletion abrogates the expression of homologous recombination (HR) genes relatively specifically, suppressing the HR DNA damage repair pathway and sensitizing cells to genotoxic stresses that cause replication fork collapse, such as Parp1 inhibitors. The proposed role for Cdk12 in regulating HR is clinically significant for two reasons. First, Cdk12 loss-of-function mutations populate high-grade serous ovarian carcinoma and castration-resistant prostate tumors raising the possibility that Cdk12 mutational status may predict the effectiveness of chemotherapeutics that target HR-deficient tumors. Second, readily available small molecule inhibitors of Cdk12 induce sensitization of HR-competent tumors to Parp1 inhibitors in vivo raising the possibility that inhibitors against Cdk12 could be used as chemotherapeutics. Despite this growing clinical interest, the mechanism behind Cdk12's regulation of HR genes remains unknown. Here we show that Cdk12 suppresses intronic polyadenylation (IPA) and that this mechanism explains the exquisite sensitivity of HR genes to Cdk12 loss. We find that Cdk12 globally enhances transcription elongation rate to kinetically suppress IPA events. Many HR genes harbor multiple IPA sites per gene, and the cumulative effect of these sites accounts for the increased sensitivity of HR genes to Cdk12. Finally, we find evidence that Cdk12 LOF mutations and deletions cause upregulation of IPA sites in HR genes in human tumors. Our results define the mechanism by which Cdk12 regulates transcription, mRNA biogenesis, and the HR pathway. This work clarifies the biological function of CDK12 and underscores its potential both as a chemotherapeutic target and as a tumor biomarker.
by Sara Jane Dubbury.
Ph. D.
Maino, Marcelo Marafon. « Expressão imunoistoquímica de CD117 no carcinoma epidermóide de esôfago ». reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2008. http://hdl.handle.net/10183/53132.
Texte intégralAim: To investigate the CD117 expression in specimens of patients with squamous cell carcinoma of the esophagus (SCCE). Methods: A pilot study was performed for CD177 immunoreactivity, using a monoclonal antibody against CD117 (DAKO), on 27 esophageal squamous cell carcinoma specimens from patients who underwent surgical resection at the Hospital de Clínicas de Porto Alegre University Hospital, Faculty of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil. As a control group, specimens of esophageal mucosa obtained from 10 healthy subjects were also studied. Results: Twenty-one (78%) males and six (12%) females with median (sd) age of 58 (8) years, ranging from 36 to 77 years. Most of the patients were of TNM stage IIb or III and mean overall survival was 21 (2 to 72) months. Cytoplasmic membrane CD117 immunoreactivity was demonstrated in only 4 (15%) out of 27 tumors and in none of the controls (0%). Conclusions: These results suggest that the decreased expression of CD117 may be due to lack of control of the cell cycle in SCCE. Additional studies are needed to better define the role of the CD117 in such tumors.
Livres sur le sujet "CDK17"
Mackiewicz, Monika. Die tumorartige Proliferation Theileria-infizierter Rinderleukozyten : Zellzyklusabhängige Phosphorylierung des Theileria annulata Surface Protein (TaSP) durch die bovine Cyclin-Dependent Kinase 1 (CDK1). 2013.
Trouver le texte intégralCCNB1, CCNB2, CCNA1, CCNA2, SYT1, SYT2, CKS2, CKS1B, CCNB3, SKP1, CDK1, RPS23, RPS27A, ZFAND4, RPS27, RPS27l, BUB1, BUB1B Could Play Significant Roles in the Aetiology of Schizophrenia by Acting As Points of Contact Between ALDH18A1 and SEC23IP (COP2). Lulu Press, Inc., 2017.
Trouver le texte intégralChapitres de livres sur le sujet "CDK17"
Hu, Dongli, et Jill M. Lahti. « CDK11 ». Dans Encyclopedia of Signaling Molecules, 995–1002. Cham : Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-67199-4_546.
Texte intégralHu, Dongli, et Jill M. Lahti. « CDK11 ». Dans Encyclopedia of Signaling Molecules, 1–8. New York, NY : Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4614-6438-9_546-1.
Texte intégralvan Roy, Frans, Volker Nimmrich, Anton Bespalov, Achim Möller, Hiromitsu Hara, Jacob P. Turowec, Nicole A. St. Denis et al. « CDK11 ». Dans Encyclopedia of Signaling Molecules, 373–79. New York, NY : Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-0461-4_546.
Texte intégralMir, Manzoor Ahmad, et Burhan Ul Haq. « CDK1 Dysregulation in Breast Cancer ». Dans Therapeutic potential of Cell Cycle Kinases in Breast Cancer, 195–210. Singapore : Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-8911-7_9.
Texte intégralShuttleworth, John. « The regulation and functions of cdk7 ». Dans Progress in Cell Cycle Research, 229–40. Boston, MA : Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1809-9_18.
Texte intégralLopes, José Manuel. « C-Kit (CD117), Gastrointestinal Stromal Tumors (GISTs) ». Dans Encyclopedia of Pathology, 137–40. Cham : Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-40560-5_1572.
Texte intégralSalaun, Patrick, Yoann Rannou et Prigent Claude. « Cdk1, Plks, Auroras, and Neks : The Mitotic Bodyguards ». Dans Hormonal Carcinogenesis V, 41–56. New York, NY : Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-69080-3_4.
Texte intégralPinhero, Reena, et Krassimir Yankulov. « Expression and Purification of Recombinant CDKs : CDK7, CDK8, and CDK9 ». Dans Methods in Molecular Biology, 13–28. New York, NY : Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-2926-9_3.
Texte intégralRodríguez-Gabriel, Miguel A. « Analyzing Cdc2/Cdk1 Activation During Stress Response in Schizosaccharomyces pombe ». Dans Methods in Molecular Biology, 383–92. New York, NY : Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0888-2_20.
Texte intégralDumitru, Ana Maria G., et Duane A. Compton. « Identifying Cyclin A/Cdk1 Substrates in Mitosis in Human Cells ». Dans Methods in Molecular Biology, 175–82. New York, NY : Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-1904-9_13.
Texte intégralActes de conférences sur le sujet "CDK17"
Bradley, Michael, Jason Marineau, Yoon Choi, Kristin Hamman, Goran Malojcic, David Orlando, Yixuan Ren et al. « Abstract 1143 : Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer ». Dans Proceedings : AACR Annual Meeting 2017 ; April 1-5, 2017 ; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-1143.
Texte intégralДенисова, Дарья Андреевна. « CYCLIN-DEPENDENT KINASES CDK8 / 19 AND THEIR INFLUENCE ON THE ORIGIN AND DEVELOPMENT OF TUMOR PROCESSES ». Dans Наука. Исследования. Практика : сборник избранных статей по материалам Международной научной конференции (Санкт-Петербург, Апрель 2020). Crossref, 2020. http://dx.doi.org/10.37539/srp290.2020.80.21.015.
Texte intégralHovdar, L., J. Rössler, P. Hechenberger, S. Rainer, K. Ausserlechner, B. Greiderer-Kleinlercher, M. Ausserlechner, C. Marth, AG Zeimet et H. Fiegl. « Effekte einer CDK12/13 Inhibition beim Ovarialkarzinom ». Dans Kongressabstracts zur Gemeinsamen Jahrestagung der Österreichischen Gesellschaft für Gynäkologie und Geburtshilfe (OEGGG) und der Bayerischen Gesellschaft für Geburtshilfe und Frauenheilkunde e.V. (BGGF). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1730504.
Texte intégralKerr, Bethany. « Abstract 2229 : CD117 expression and activation in prostate cancer progression ». Dans Proceedings : AACR 106th Annual Meeting 2015 ; April 18-22, 2015 ; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2229.
Texte intégralHarris, Koran, Lihong Shi, Taylor Peak, Stephanie Sanders, Aleksander Skardal et Bethany Kerr. « Abstract 1983 : CD117 expression and activation induce prostate cancer metastasis ». Dans Proceedings : AACR Annual Meeting 2017 ; April 1-5, 2017 ; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-1983.
Texte intégralFernandes, Vanessa C., Thales C. Nepomuceno, Renato S. Carvalho, Guilherme Suarez-Kurtz, Alvaro N. Monteiro et Marcelo A. Carvalho. « Abstract A04 : Structural and functional caracterization of BARD1/CDK13 interaction ». Dans Abstracts : AACR International Conference held in cooperation with the Latin American Cooperative Oncology Group (LACOG) on Translational Cancer Medicine ; May 4-6, 2017 ; São Paulo, Brazil. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1557-3265.tcm17-a04.
Texte intégralShi, Lihong, Brittni Foster, Koran Harris, Aleksander Skardal et Bethany A. Kerr. « Abstract B027 : CD117 tyrosine kinase activation drives prostate cancer aggressiveness ». Dans Abstracts : AACR Special Conference : Prostate Cancer : Advances in Basic, Translational, and Clinical Research ; December 2-5, 2017 ; Orlando, Florida. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.prca2017-b027.
Texte intégralGarcia-Martinez, Juan Manuel, Andreas Wernitznig, Joerg Rinnenthal, Maria Antonietta Impagnatiello, Frank Hilberg, Craig Giragossian, Norbert Kraut, Mark Pearson et Klaus-Peter Kuenkele. « Abstract 2051 : BI 905711, a novel CDH17-targeting TRAILR2 agonist, effectively triggers tumor cell apoptosis and tumor regressions selectively in CDH17-positive colorectal cancer models ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2051.
Texte intégralGarcia-Martinez, Juan Manuel, Andreas Wernitznig, Joerg Rinnenthal, Maria Antonietta Impagnatiello, Frank Hilberg, Craig Giragossian, Norbert Kraut, Mark Pearson et Klaus-Peter Kuenkele. « Abstract 2051 : BI 905711, a novel CDH17-targeting TRAILR2 agonist, effectively triggers tumor cell apoptosis and tumor regressions selectively in CDH17-positive colorectal cancer models ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2051.
Texte intégralChilà, R., N. Panini, F. Guffanti et G. Damia. « PO-040 Characterisation of CDK12 knocked out ovarian cancer cell lines ». Dans Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.85.
Texte intégral